<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Verrica Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc</link>
<description>Latest news and press releases for Verrica Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/verrica-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d3c378dffbe2df120b26.webp</url>
<title>Verrica Pharmaceuticals Inc</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc</link>
</image>
<item>
<title>Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-acceptance-of-late-breaking-abstract-highlighting-potential-abscopal-effect-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-upcoming-2026-society-for-investigative-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-acceptance-of-late-breaking-abstract-highlighting-potential-abscopal-effect-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-at-the-upcoming-2026-society-for-investigative-dermatology-annual-meeting</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Mon, 06 Apr 2026 12:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026Ev</description>
</item>
<item>
<title>Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – –</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-a-corporate-update-on-march-11-2026-8</guid>
<pubDate>Thu, 05 Mar 2026 13:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston. TD Cowen 46th Annual Health Care Conference, March 2-4, 2026Event details:Date: Mon</description>
</item>
<item>
<title>Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-appoints-chris-chapman-130000503</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-appoints-chris-chapman-130000503</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. “It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an ex</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-launch-ycanth-130000654</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-launch-ycanth-130000654</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd. (“Torii”), a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum (“molluscum”). “We would like to congratulate our partner, Torii, on th</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-first-patient-130000058</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-first-patient-130000058</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-private-placement-130000158</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-private-placement-130000158</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica’s Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and sellin</description>
</item>
<item>
<title>Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-third-quarter-210500214</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-third-quarter-210500214</guid>
<pubDate>Fri, 14 Nov 2025 21:05:00 GMT</pubDate>
<description>– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Appli</description>
</item>
<item>
<title>Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-presents-data-vp-130000866</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-presents-data-vp-130000866</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>– Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive T-regulatory cells – – Findings provide mechanistic immunologic support for clinical efficacy previously reported, including 97% calculated objective response rate and 51% complete histologic clearance rate – – Coupled with VP-315’s previously reported safety profile, these results highlight VP-315’s potenti</description>
</item>
<item>
<title>Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-receives-positive-feedback-200500770</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-receives-positive-feedback-200500770</guid>
<pubDate>Mon, 20 Oct 2025 20:05:00 GMT</pubDate>
<description>– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 studies are required – – Verrica is initiating activities to support this regulatory submission, which could be filed as early as Q4 2026 – WEST CHESTER, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”)</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-present-data-vp-200500029</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-present-data-vp-200500029</guid>
<pubDate>Tue, 07 Oct 2025 20:05:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-development-partner-120000025</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-development-partner-120000025</guid>
<pubDate>Fri, 19 Sep 2025 12:00:00 GMT</pubDate>
<description>– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventi</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-participate-h-c-110000172</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-participate-h-c-110000172</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Conference, Sep</description>
</item>
<item>
<title>Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-second-quarter-200100872</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-second-quarter-200100872</guid>
<pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
<description>– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical – – Completed Successful End of Phase 2 Meeting for VP-315 for Basal Cell Carcinoma; Company is preparing for the Phase 3 program and exploring non-dilutive opportunities for financing further development – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTE</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-report-second-quarter-110000359</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-report-second-quarter-110000359</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update. Individuals may participate in</description>
</item>
<item>
<title>Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-strong-growth-110000912</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-reports-strong-growth-110000912</guid>
<pubDate>Wed, 09 Jul 2025 11:00:00 GMT</pubDate>
<description>– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH® dispensed applicator units in Q2 2025 – – Company reports receipt of $8 million milestone payment from its Japanese development partner, Torii Pharmaceutical, for initiation of global Phase 3 program in common warts – WEST CHESTER, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications</description>
</item>
<item>
<title>Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-amendment-collaboration-110000868</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-announces-amendment-collaboration-110000868</guid>
<pubDate>Tue, 01 Jul 2025 11:00:00 GMT</pubDate>
<description>– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025 – – Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget – – Common warts affec</description>
</item>
<item>
<title>Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York</title>
<link>https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-participate-jefferies-global-120000380</link>
<guid isPermaLink="true">https://6ix.com/company/verrica-pharmaceuticals-inc/news/verrica-pharmaceuticals-participate-jefferies-global-120000380</guid>
<pubDate>Wed, 28 May 2025 12:00:00 GMT</pubDate>
<description>WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City. Jefferies Global Healthcare Conference, June 3-5, 2025Event details:Date: We</description>
</item>
</channel>
</rss>